Drug Trial Radar · NCT00618228
Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions
Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jan 2004
Primary completion
Jan 2004
Study completion Jan 2004
Sponsor
- Lead sponsor
- Roxane LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to assess bioequivalence of a potential generic 750 mg balsalazide disodium capsule formulation compared with Salix Pharmaceutical's 750 mg balsalazide disodium capsule, Colazal, following a single 750 mg dose, under fasting conditions.
Conditions
- Ulcerative Colitis
Interventions
BalsalazideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- BioequivalenceTime frame: Baseline, Two period, 7 day washout
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novum Pharmaceuticals Research Services
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.